Holen Sie sich die Stockscreener-App
53.88
1.12%
0.5775
Schlusskurs vom Vortag:
$53.30
Offen:
$53.35
24-Stunden-Volumen:
1.06M
Relative Volume:
0.41
Marktkapitalisierung:
$10.35B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
20.03
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+0.01%
1M Leistung:
+4.73%
6M Leistung:
-5.25%
1J Leistung:
-19.33%
1-Tages-Spanne:
$53.11
$54.02
1-Wochen-Bereich:
$52.55
$54.66
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.86 | 10.24B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.97 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.65 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.75 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Arrowstreet Capital Limited Partnership Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
August 2026 Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Jump Financial LLC Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Technical Reactions to BMRN Trends in Macro Strategies - news.stocktradersdaily.com
BioMarin Pharmaceutical Inc. (BMRN): A bull case theory - MSN
Schroder Investment Management Group Trims Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What margin trends mean for BioMarin Pharmaceutical Inc. stockJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Dodge & Cox - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyJuly 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Insider Monkey
BioMarin Loses Hormone Patent In Europe - Law360
BioMarin Pharmaceutical (NASDAQ:BMRN) Lowered to "Market Perform" Rating by Leerink Partners - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to "Hold" at Leerink Partnrs - MarketBeat
Is BioMarin Pharmaceutical Inc. stock undervalued vs historical averagesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - Newser
Can BioMarin Pharmaceutical Inc. (BM8) stock withstand sector downturns2025 Key Lessons & Technical Pattern Based Signals - Newser
Mackenzie Financial Corp Grows Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
2,043,879 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Norges Bank - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform By Investing.com - Investing.com South Africa
Uber To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
BMRN Experiences Downgrade and Price Target Cut by Leerink Partn - GuruFocus
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Sio Capital Management LLC - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform - Investing.com
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 - marketscreener.com
Hsbc Holdings PLC Boosts Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Leerink Partners downgrades BioMarin Pharmaceutical (BMRN) - MSN
Korea Investment CORP Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
Edgestream Partners L.P. Has $7.12 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Quadrature Capital Ltd Purchases New Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pullback Watch: Is BioMarin Pharmaceutical Inc. stock oversold or undervaluedQuarterly Market Review & Stock Market Timing Techniques - BỘ NỘI VỤ
Icon Advisers Inc. Co. Has $973,000 Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Charles Schwab Investment Management Inc. Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Vinva Investment Management Ltd Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Thornburg Investment Management Inc. Sells 7,417 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Prudential Financial Inc. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Rhumbline Advisers - MarketBeat
Is BioMarin Pharmaceutical Inc. stock oversold or undervaluedJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - BỘ NỘI VỤ
BioMarin Pharmaceutical Inc. (BM8.DE) Stock Analysis: Can This Biotech Rebound? - Meyka
Inceptionr LLC Acquires 30,021 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Handelsbanken Fonder AB Sells 7,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Rhenman & Partners Asset Management AB Sells 115,350 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Trading the Move, Not the Narrative: (BMRN) Edition - news.stocktradersdaily.com
BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance - Sahm
The Past Three Years for BioMarin Pharmaceutical (NASDAQ:BMRN) Investors Has Not Been Profitable - 富途牛牛
Summit Global Investments Increases Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Will BioMarin’s (BMRN) Raised Outlook After Solid Revenue Growth Shift Its Investment Narrative? - Sahm
Prudential PLC Purchases 24,114 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):